Radiobiology for particle therapy

Size: px
Start display at page:

Download "Radiobiology for particle therapy"

Transcription

1 Radiobiology for particle therapy Marco Durante CNAO-NIRS meeting, Pavia INFN Workshop, Napoli,

2 2 The radiobiological adavantages of particle therapy Jakob et al., PNAS 2009 PIDE database Friedrich et al., J. Radiat. Res. 2013

3 3 March 2014: 44 proton/7 heavy ion centers Under construction: 25 proton/ 3 heavy ion centers Only in USA, 27 new centers expected by 2017 NuPECC report Nuclear Physics in Medicine, 2014

4 CLINICAL INDICATIONS Established clinical indications - Skull base tumors - Spine tumors - Eye tumors (p) Solid literature results - Pediatric tumors (p) - Head and Neck tumors - Prostate tumors Courtesy of Marco Krengli, Novara UK overseas clinical indications for protontherapy, courtesy of Simon Jolly, UCL UK list of typical indications <2% patients

5 ITALIAN NETWORK FOR HADRONTHERAPY (p+,ions, 3 rooms with fixed beams) CNAO Pavia ATreP Trento (p+, 2 gantries) from 2014 EXISTING CENTRES FINANCED CENTRES Operating INTEREST FOR PROTONS Working Group of AIRO, 2003, 2008, 2009 ( new cases/year with conventional RT): protontherapy - elective: pts/year protontherapy clinical trials: pts/year therapy with 12 C-ions cl. trials pts/year Conclusions of AIRO: 1 centre for ions 4-5 centres for protons Catana (p+,only eye) (p+)

6 Treatment plans with protons: prostate Courtesy of Reinhold Schulte, LLUMC

7 SPINE TUMORS PROTON THERAPY (Weber et al., IJROBP 2004)

8 Protontherapy in paediatric oncology Courtesy of Jeffrey Dihn MD Anderson, Houston, TX

9 Secondary Malignant Neoplasms (SMN) in particle therapy Radiation Absorbed Dose Risk of SMN Incidence Comparison of relative radiation dose distribution with the corresponding relative risk distribution for radiogenic second cancer incidence and mortality. This 9-year old girl received craniospinal irradiation for medulloblastoma using passively scattered proton beams. The color scale illustrates the difference for absorbed dose, incidence and mortality cancer risk in different organs. Newhauser & Durante, Nature Rev. Cancer 2011 Risk of SMN Mortality

10 AAPM poll, August 2012 What is the main obstacle to proton therapy replacing X-rays? 22% 38% 40% Cost/benefit ratio Range uncertainties Protons will never replace X-rays

11 New cancers where charged particles may potentially lead to a breakthrough - Lung - Pancreas - Local recurrence of rectal cancer - Breast - Hepatocellular carcinoma - Glioblastoma - Combined treatments to improve survival Siegel et al., CA Cancer J Clin 2013

12 Lung cancer: 2 nd in incidence and 1 st in mortality for both sexes in US HDSF by CIRT 40 GyE, 1 fraction, 3 fields, gating Tsujii et al. Carbon Ion Radiotherapy, Springer-Verlag, 2014

13 Intrafractional movements and hypofractionation in NSCLC courtesy of Chritoph Bert, University of Erlangen & GSI Courtesy of M. Söhn, LMU

14 Radiosurgery (SBRT): the new frontier in stereotactic imageguided radiotherapy Stage I (T1N0M0) NSCLC Oligometastases Hepatocellular carcinoma Advanced (T2-T4; >3 cm) NSCLC Localized tumors in kidney, prostate, pancreas, adrenal gland, pravertebal tumors etc. BED a/b = nd [1 + d/(a/b) ] (LQ model) SBRT only possible thanks to IGRT and to the low mean dose to parallel organs Brown et al., Int. J. Radiat. Oncol. Biol. Phys. 2013

15 15 RBE and hypofractionation: differential decrease in normal and tumor tissue HIMAC TPS Scholz et al., Phys. Med Ando et al., Radiat. Prot. Dosim. 2002

16 Ions vs. X-rays in SBRT for NSCLC TCP vs. BED for Stage I NSCLC by X-rays or charged particles Durante, Br. J. Radiol HIMAC vs. LEM: dependence of the RBE on the dose/fraction d Steinsträter et al., Int. J. Radiat. Oncol. Biol. Phys. 2012

17 Re-oxygenation in radiosurgery Models of oligofractionation predict failure for hypoxic tumors re-oxygenation between fractions is in fact essential for local control for at least some tumors (H&N, cervix, pancreas, prostate). if the number of fractions is severely reduced then this vital process will be rendered less effective heavy ions

18 A new radiobiology for high-dose, single fraction stereotactic radiosurgery (hypofractionation, SBRT)? 18 Girdhani et al., Radiat. Res Kolesnick et al., Science 2008

19 Pancreas cancer 4th cause of cancer death in USA Median survival time 9 months Even after surgery, survival at 5 years <12% Resectable preooperative treatment Locally advanced + gemcitabine 1,000 mg/m 2 Tsujii et al. Carbon Ion Radiotherapy, Springer-Verlag, 2014

20 po2 measurements in pancreatic tumors and normal pancreatic tissue Tumor Normal Tissue Patient Med po2 %<2.5mmHg Med po2 %<2.5mmHg Tumor (Koong AC, IJROBP 48, 2000)

21 Oxygen effect in vivo Hirayama et al., Mutat. Res. 2013

22 OER(pO 2, LET) model for adaptive particle treatment planning Scifoni et al., Phys. Med. Biol ; 2β α 2β α β N) (c β N c α (N) D x x 2 x x x 2 T i i T i i i bio Krämer & Scholz, Phys. Med. Biol ), ( / ), ( ' ), ( / ), ( ' i i i i i i i i i i i i p L OER p L p L OER p L b b a a

23 OER along an irradiated volume for different ions C, O, p and soon He Joining OER driven and Multiion modality in next TRiP release Krämer et al., J. Phys. Chem. Solids 2013

24 Radiotherapy for Breast Cancer About 200,000 new cases per year in U.S Most affected at the most productive part of life Most patients survive (> 2 millions survivors) Increased risk of cardiac toxicity and second malignancies Horror stories from side effects of radiation leads many women to choose mastectomy over radiotherapy Darby et al. N Engl J Med Mar 14

25 Andrew Chang, Presentation at the 2013 Proton Breast Cancer Workshop, Phoenix, AZ Should phase 3 randomized be done for this? IMRT --- Proton = Difference

26 Treatment plans with protons: breast MacDonald et al, Int J Radiat Oncol Biol Phys, 1-7, 2013

27 27 RBE in protontherapy Grün et al., Med. Phys. 2013

28 28 Combined treatments: beyond LC High risk prostate cancer patients RT + ADT Bolla et al., Lancet 2012 Wan et al., Nat. Med. 2013

29 29 IGRT+immunotherapy Melanoma Ipilimumab (anti-ctla4) Postow et al.; Hiniker et al. N.Eng. J. Med. 366; 2012 Oligometastasis Sunitinib (anti-stat3 and VEGF) Tong et al., PLoS One 7; 2012 Chondrosarcoma protons + sunitinib Dallas et al., J. Med. Case Rep. 6; 2012

30 Treatment plan for the abdominal tumor 6M after Treatment Para-aortic metastasis before treatment

31 Radioimmunology mechanisms Durante et al., Trends Mol. Med

32 What do we need? 1. A widespread and effective use of particle therapy can only be possible by expanding the clinical indications 2. Accelerator physics should reduce costs (compact accelerators, innovative approaches...) 3. Medical physics should reduce range uncertainty and treatment time, making possible the treatment of moving targets, oligometastasis, benign lesions Radiobiology is the only possible line potentially leading to breakthroughs in cancer therapy, especially for highly lethal, incurable diseases 5. Hypofractionation, adaptive TP and combined treatments are among the most promising strategies CNAO-NIRS meeting, Pavia

33

34 M. Durante (Director) G. Kraft (Helmholtz Professor) G. Taucher-Scholz (DNA damage) S. Ritter (Stem cells) C. Fournier (Late effects) C. Hartel (Clinical radiobiology) M. Scholz (Biophysical modelling) M. Krämer (Treatment planning) C. Graeff (Moving targets) C. La Tessa (Dosimetry)

Hypofractionation in particle therapy. Marco Durante

Hypofractionation in particle therapy. Marco Durante Hypofractionation in particle therapy Marco Durante 29.04.2014 Radiosurgery (SBRT): the new frontier in stereotactic imageguided radiotherapy Stage I (T1N0M0) NSCLC Oligometastases Hepatocellular carcinoma

More information

Medical physics is beautiful

Medical physics is beautiful Translational research in particle therapy Marco Durante Medical physics is beautiful Pisa, 31.10.2014 Relative dose 1. 2 1. 0 Tumor Durante & Loeffler, Nature Rev Clin Oncol 2010 0. 8 Normal tissue 0.

More information

Ion Beam Therapy should we prioritise research on helium beams?

Ion Beam Therapy should we prioritise research on helium beams? Ion Beam Therapy should we prioritise research on helium beams? Stuart Green Medical Physics University Hospital Birmingham NHS Trust Follow-up from the EUCARD2 workshop, ION Beam Therapy: Clinical, Scientific

More information

Clinical Results of Carbon Ion Radiotherapy: The Heidelberg Experience

Clinical Results of Carbon Ion Radiotherapy: The Heidelberg Experience Clinical Results of Carbon Ion Radiotherapy: The Heidelberg Experience Stephanie E. Combs, MD Department of Radiation Oncology University of Heidelberg, Germany Carbon ion RT at GSI Active beam delivery

More information

III. Proton-therapytherapy. Rome SB - 5/5 1

III. Proton-therapytherapy. Rome SB - 5/5 1 Outline Introduction: an historical review I Applications in medical diagnostics Particle accelerators for medicine Applications in conventional radiation therapy II III IV Hadrontherapy, the frontier

More information

NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18)

NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18) BONE (Version 2.2018, 03/28/18) NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) Radiation Therapy Specialized techniques such as intensity-modulated RT (IMRT); particle beam RT with protons, carbon ions,

More information

Out-of-field dosimetry in radiotherapy for input to epidemiological studies. Roger Harrison

Out-of-field dosimetry in radiotherapy for input to epidemiological studies. Roger Harrison MELODI 7th Workshop, 9 11 November 2015 Helmholtz Zentrum München Next Generation Radiation Protection Research Out-of-field dosimetry in radiotherapy for input to epidemiological studies Roger Harrison

More information

Current Status and Future Medical Perspectives at MedAustron. U. Mock EBG MedAustron GmbH

Current Status and Future Medical Perspectives at MedAustron. U. Mock EBG MedAustron GmbH Current Status and Future Medical Perspectives at MedAustron U. Mock EBG MedAustron GmbH Cancer treatment facility Ion beam therapy with protons and carbon ions Research facility Medical physics Radiobiology

More information

HEALTH RISKS FROM EXPOSURE TO FAST NEUTRONS. Prof. Marco Durante

HEALTH RISKS FROM EXPOSURE TO FAST NEUTRONS. Prof. Marco Durante HEALTH RISKS FROM EXPOSURE TO FAST NEUTRONS Prof. Marco Durante Risk from neutrons Risk from exposure to fission spectrum neutrons has been extensively studied in the 60 s at nuclear reactors using animal

More information

SBRT in early stage NSCLC

SBRT in early stage NSCLC SBRT in early stage NSCLC Optimal technique and tumor dose Frank Zimmermann Clinic of Radiotherapy and Radiation Oncology University Hospital Basel Petersgraben 4 CH 4031 Basel radioonkologiebasel.ch Techniques

More information

8th Warren K. Sinclair Keynote Address 47th Annual NCRP Meeting Bethesda, MD, March 7, 2011 Heavy ions in therapy and space: benefits and risks

8th Warren K. Sinclair Keynote Address 47th Annual NCRP Meeting Bethesda, MD, March 7, 2011 Heavy ions in therapy and space: benefits and risks 8th Warren K. Sinclair Keynote Address 47th Annual NCRP Meeting Bethesda, MD, March 7, 2011 Heavy ions in therapy and space: benefits and risks Marco Durante What are heavy ions? 50 um What are heavy ions?

More information

Dosimetry for Epidemiology Cohorts Who Receive Radiation Therapy

Dosimetry for Epidemiology Cohorts Who Receive Radiation Therapy Dosimetry for Epidemiology Cohorts Who Receive Radiation Therapy Wayne Newhauser, PhD Eurados Winter School, Milan, 2016 Introduction About 1 in 2 men and women born today will be diagnosed with some form

More information

PROGRESS IN HADRONTHERAPY

PROGRESS IN HADRONTHERAPY PROGRESS IN HADRONTHERAPY Saverio Braccini TERA Foundation for Oncological Hadrontherapy IPRD06 - Siena - 01.10.06 - SB 1 Outline Introduction Radiation therapy with X rays and hadrontherapy Hadrontherapy

More information

Status of H 1 and C 12

Status of H 1 and C 12 Status of H 1 and C 12 Herman Suit No Conflict of Interest 1 Goal of a New Treatment Modality Tumor Control Probability or No in Complication Rate 2 Truism No Advantage to: any Patient for any Radiation

More information

Proton and heavy ion radiotherapy: Effect of LET

Proton and heavy ion radiotherapy: Effect of LET Proton and heavy ion radiotherapy: Effect of LET As a low LET particle traverses a DNA molecule, ionizations are far apart and double strand breaks are rare With high LET particles, ionizations are closer

More information

Advances in external beam radiotherapy

Advances in external beam radiotherapy International Conference on Modern Radiotherapy: Advances and Challenges in Radiation Protection of Patients Advances in external beam radiotherapy New techniques, new benefits and new risks Michael Brada

More information

International Open Laboratory at NIRS (Second Term)

International Open Laboratory at NIRS (Second Term) Ryuichi Okayasu, Ph.D. Scientific Secretary E-mail: rokayasu@nirs.go.jp The second term NIRS International Open Laboratory (IOL) was started in April 2011 with four new units and its term was completed

More information

Future of Radiation Therapy

Future of Radiation Therapy Future of Radiation Therapy JP Morgan Healthcare Conference January 12, 2016 Deepak Khuntia, MD, VP of Medical Affairs Patrick Kupelian, MD, VP of Clinical Affairs Cancer as a cause of death CANCER TREATMENT

More information

Nuclear Data for Radiation Therapy

Nuclear Data for Radiation Therapy Symposium on Nuclear Data 2004 Nov. 12, 2004 @ JAERI, Tokai Nuclear Data for Radiation Therapy ~from macroscopic to microscopic~ Naruhiro Matsufuji, Yuki Kase and Tatsuaki Kanai National Institute of Radiological

More information

Overview of Advanced Techniques in Radiation Therapy

Overview of Advanced Techniques in Radiation Therapy Overview of Advanced Techniques in Radiation Therapy Jacob (Jake) Van Dyk Manager, Physics & Engineering, LRCP Professor, UWO University of Western Ontario Acknowledgements Glenn Bauman Jerry Battista

More information

Particle Radiation Therapy: CurrentStatus Indications -Results

Particle Radiation Therapy: CurrentStatus Indications -Results Particle Radiation Therapy: CurrentStatus Indications -Results Eugen B. Hug Center for Proton Therapy Paul Scherrer Institute and University of Zürich Switzerland Particle Radiation Therapy: Selection

More information

Analytical Methods for Normal- Tissue Dose Reconstructions. Acknowledgments. Disclosures. Learning Objectives 8/2/2017. Wayne Newhauser, PhD

Analytical Methods for Normal- Tissue Dose Reconstructions. Acknowledgments. Disclosures. Learning Objectives 8/2/2017. Wayne Newhauser, PhD Analytical Methods for Normal- Tissue Dose Reconstructions Wayne Newhauser, PhD newhauser@lsu.edu AAPM Annual Meeting, August 2, 2017 Acknowledgments Bella Bowman Foundation Numerous current and former

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: charged_particle_radiotherapy 3/12/96 5/2017 5/2018 5/2017 Description of Procedure or Service Charged-particle

More information

ACR TXIT TM EXAM OUTLINE

ACR TXIT TM EXAM OUTLINE ACR TXIT TM EXAM OUTLINE Major Domain Sub-Domain 1 Statistics 1.1 Study design 1.2 Definitions of statistical terms 1.3 General interpretation & analysis 1.4 Survival curves 1.5 Specificity/sensitivity

More information

Stereotactic radiotherapy

Stereotactic radiotherapy Stereotactic radiotherapy Influence of patient positioning and fixation on treatment planning - clinical results Frank Zimmermann Institut für Radioonkologie Universitätsspital Basel Petersgraben 4 CH

More information

HADRONTHERAPY: a new frontier for cancer treatment

HADRONTHERAPY: a new frontier for cancer treatment Razionale HADRONTHERAPY: a new frontier for cancer treatment September, 19 20 2014 Hadrontherapy is a specific type of localized radiation therapy, which uses fast hadrons (charged particles made of quarks)

More information

FROM ICARO1 TO ICARO2: THE MEDICAL PHYSICS PERSPECTIVE. Geoffrey S. Ibbott, Ph.D. June 20, 2017

FROM ICARO1 TO ICARO2: THE MEDICAL PHYSICS PERSPECTIVE. Geoffrey S. Ibbott, Ph.D. June 20, 2017 FROM ICARO1 TO ICARO2: THE MEDICAL PHYSICS PERSPECTIVE Geoffrey S. Ibbott, Ph.D. June 20, 2017 1 DISCLOSURES My institution holds Strategic Partnership Research Agreements with Varian, Elekta, and Philips

More information

Modelling the induction of cell death and chromosome damage by therapeutic protons

Modelling the induction of cell death and chromosome damage by therapeutic protons Modelling the induction of cell death and chromosome damage by therapeutic protons M.P. Carante 1,2 and F. Ballarini 1,2, * 1 University of Pavia, Physics Department, Pavia, Italy 2 INFN, Sezione di Pavia,

More information

DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES

DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES Marco Krengli Radiotherapy, Department of Translational Medicine, University of Piemonte Orientale A. Avogadro THE STANDARD OF CARE

More information

Radiobiology of high dose per fraction

Radiobiology of high dose per fraction Radiobiology of high dose per fraction Michael Joiner Wayne State University Radiation Oncology Detroit, Michigan joinerm@wayne.edu AAPM 2014 Historically Research focused on clinically relevant doses

More information

State of the Art Radiotherapy for Pediatric Tumors. Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center

State of the Art Radiotherapy for Pediatric Tumors. Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center State of the Art Radiotherapy for Pediatric Tumors Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center Introduction Progress and success in pediatric oncology Examples of low-tech and high-tech

More information

Flattening Filter Free beam

Flattening Filter Free beam Dose rate effect in external radiotherapy: biology and clinic Marta Scorsetti, M.D. Radiotherapy and Radiosurgery Dep., Istituto Clinico Humanitas, Milan, Italy Brescia October 8th/9th, 2015 Flattening

More information

New Radiation Treatment Modalities in the Treatment of Lung Cancer

New Radiation Treatment Modalities in the Treatment of Lung Cancer New Radiation Treatment Modalities in the Treatment of Lung Cancer David Perry, M.D. Chief, Radiation Oncology Medical Director, CyberKnife Radiosurgery Center Medstar Franklin Square Medical Center Definitions

More information

Prof. Dr. Thomas Haberer Scientific-technical Director Heidelberg Iontherapy Center

Prof. Dr. Thomas Haberer Scientific-technical Director Heidelberg Iontherapy Center The Heidelberg Ion Beam Therapy Center A Hospital-based Facility Dedicated to Precision and Flexibility Prof. Dr. Thomas Haberer Scientific-technical Director Heidelberg Iontherapy Center Carbon Ion Therapy

More information

PTCOG 46. Educational Workshop Session IV. Head & Neck CLINICAL. J. Mizoe (NIRS, Japan)

PTCOG 46. Educational Workshop Session IV. Head & Neck CLINICAL. J. Mizoe (NIRS, Japan) PTCOG 46 Educational Workshop Session IV CLINICAL Head & Neck J. Mizoe (NIRS, Japan) Photon X-Ray γ-ray Fast Neutron Non-Charged Radiation Electron Proton Helium Light Ion Heavy Particle Carbon Neon Argon

More information

Radiobiology of fractionated treatments: the classical approach and the 4 Rs. Vischioni Barbara MD, PhD Centro Nazionale Adroterapia Oncologica

Radiobiology of fractionated treatments: the classical approach and the 4 Rs. Vischioni Barbara MD, PhD Centro Nazionale Adroterapia Oncologica Radiobiology of fractionated treatments: the classical approach and the 4 Rs Vischioni Barbara MD, PhD Centro Nazionale Adroterapia Oncologica Radiobiology It is fundamental in radiation oncology Radiobiology

More information

Use of radiation to kill diseased cells. Cancer is the disease that is almost always treated when using radiation.

Use of radiation to kill diseased cells. Cancer is the disease that is almost always treated when using radiation. Radiation Therapy Use of radiation to kill diseased cells. Cancer is the disease that is almost always treated when using radiation. One person in three will develop some form of cancer in their lifetime.

More information

Clinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology

Clinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology Clinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology Abdominal SBRT: Clinical Aspects Rationales for liver and pancreas SBRT

More information

PHYS 383: Applications of physics in medicine (offered at the University of Waterloo from Jan 2015)

PHYS 383: Applications of physics in medicine (offered at the University of Waterloo from Jan 2015) PHYS 383: Applications of physics in medicine (offered at the University of Waterloo from Jan 2015) Course Description: This course is an introduction to physics in medicine and is intended to introduce

More information

Accuracy Requirements and Uncertainty Considerations in Radiation Therapy

Accuracy Requirements and Uncertainty Considerations in Radiation Therapy Departments of Oncology and Medical Biophysics Accuracy Requirements and Uncertainty Considerations in Radiation Therapy Introduction and Overview 6 August 2013 Jacob (Jake) Van Dyk Conformality 18 16

More information

Summary Talk of the Workshop

Summary Talk of the Workshop Medical experience History of IBT 1954 1975 1976 1977 1982 1987 1992 Pituitary 1st He pt Treatment 1st C, Ne pt Eye treatment Phase-1 He Phase I-II Ne Phase I-II Ne & He 1st Comp Tx Plan 3D planning LBNL

More information

This LCD recognizes these two distinct treatment approaches and is specific to treatment delivery:

This LCD recognizes these two distinct treatment approaches and is specific to treatment delivery: National Imaging Associates, Inc. Clinical guidelines STEREOTACTIC RADIOSURGERY (SRS) AND STEREOTACTIC BODY RADIATION THERAPY (SBRT) CPT4 Codes: 77371, 77372, 77373 LCD ID Number: L33410 J-N FL Responsible

More information

The Royal College of Radiologists RCR-Cyclotron Trust Visiting Fellowships 2017 (Clinical Oncology) POST-VISIT REPORT

The Royal College of Radiologists RCR-Cyclotron Trust Visiting Fellowships 2017 (Clinical Oncology) POST-VISIT REPORT The Royal College of Radiologists RCR-Cyclotron Trust Visiting Fellowships 2017 (Clinical Oncology) POST-VISIT REPORT PLEASE NOTE: This report must be completed and emailed to the RCR within 2 months of

More information

肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部

肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation

More information

Role of protons, heavy ions and BNCT in brain tumors

Role of protons, heavy ions and BNCT in brain tumors Role of protons, heavy ions and BNCT in brain tumors Prof G K Rath Head, NCI (AIIMS-2) Chief, Dr. BRA IRCH, Professor Radiation Oncology All India Institute of Medical Sciences, New Delhi 1 Overview of

More information

Protones/Fotones. Dra. Berta Roth

Protones/Fotones. Dra. Berta Roth Protones/Fotones Dra. Berta Roth The Best in Proton Protect, Therapy, Enhance Today and and Save Tomorrow Lives Advances in Science, biology, physics, imaging allows: More efficient and better tolerated

More information

Activities at the Heidelberg Ion Therapy Center (HIT)

Activities at the Heidelberg Ion Therapy Center (HIT) Activities at the Heidelberg Ion Therapy Center (HIT) The people A. Mairani (now INFN), F. Sommerer (Uniklinikum Heidelberg), I. Rinaldi (DKFZ Heidelberg), K. Parodi (HIT and University of Heidelberg)

More information

Clinical Treatment Planning

Clinical Treatment Planning Radiation Therapy Services Benefits to Change for the CSHCN Services Program Effective October 1, 2008, benefits for radiation therapy services will change for the Children with Special Health Care Needs

More information

HALF. Who gets radiotherapy? Who gets radiotherapy? Half of all cancer patients get radiotherapy. By 1899 X rays were being used for cancer therapy

HALF. Who gets radiotherapy? Who gets radiotherapy? Half of all cancer patients get radiotherapy. By 1899 X rays were being used for cancer therapy The Physical and Biological Basis of By 1899 X rays were being used for cancer therapy David J. Brenner, PhD, DSc Center for Radiological Research Department of Radiation Oncology Columbia University Medical

More information

The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology

The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology (specifically, lung cancer) 2/10/18 Jeffrey Kittel, MD Radiation Oncology, Aurora St. Luke s Medical Center Outline The history

More information

The Advantages of Particle Therapy and the Status of the Heidelberg Iontherapy Center

The Advantages of Particle Therapy and the Status of the Heidelberg Iontherapy Center The Advantages of Particle Therapy and the Status of the Heidelberg Iontherapy Center Thomas Haberer, Scientific Technical Director, Heidelberg Ion Therapy Center Situation / Indications 2/3 patients suffer

More information

Charged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions

Charged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions Charged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions Policy Number: 8.01.10 Last Review: 11/2017 Origination: 11/2006 Next Review: 11/2018 Policy Blue Cross and Blue Shield of

More information

Biological Optimization of Hadrontherapy. Uwe Oelfke

Biological Optimization of Hadrontherapy. Uwe Oelfke 4/2/2012 page 1 Biological Optimization of Hadrontherapy Uwe Oelfke DKFZ Heidelberg (E040) Im Neuenheimer Feld 280 69120 Heidelberg, Germany u.oelfke@dkfz.de 4/2/2012 page 2 Contents Introduction and General

More information

DEPARTMENT OF ONCOLOGY ELECTIVE

DEPARTMENT OF ONCOLOGY ELECTIVE DEPARTMENT OF ONCOLOGY ELECTIVE 2015-2016 www.uwo.ca/oncology Oncology Elective Program Administrator: Ms. Kimberly Trudgeon Room A4-901C (Admin) LHSC London Regional Cancer Centre (Victoria Campus) Phone:

More information

Non-classical radiobiology relevant to high-doses per fraction

Non-classical radiobiology relevant to high-doses per fraction Non-classical radiobiology relevant to high-doses per fraction Michael Joiner Wayne State University Radiation Oncology Detroit, Michigan joinerm@wayne.edu Why reconsider high dose fractions? Because we

More information

Present status and future of Proton beam therapy

Present status and future of Proton beam therapy Present status and future of Proton beam therapy Description At present, the types of proven treatment for cancer are surgery, radiotherapy, and chemotherapy. Depending on the characteristics of cancer

More information

Radiation Oncology. Initial Certification Qualifying (Computer-based) Examination: Study Guide for Radiation and Cancer Biology

Radiation Oncology. Initial Certification Qualifying (Computer-based) Examination: Study Guide for Radiation and Cancer Biology Radiation Oncology Initial Certification Qualifying (Computer-based) Examination: Study Guide for Radiation and Cancer Biology This exam tests your knowledge of the principles of cancer and radiation biology

More information

Review of Hadron machines for cancer therapy

Review of Hadron machines for cancer therapy Review of Hadron machines for cancer therapy M. Kanazawa NIRS cancer therapy with hadron (p, C) Clinical studies at New ideas of accelerators Compact facilities (p, C) Depth dose distribution Carbon, proton

More information

HEAVY PARTICLE THERAPY

HEAVY PARTICLE THERAPY HEAVY PARTICLE THERAPY DR. G.V. GIRI KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY ICRO 2012 BHATINDA HEAVY PARTICLES USED IN A EFFORT TO IMPROVE TUMOR CONTROL, THAT DO NOT RESPOND TO PHOTONS OR ELECTRONS BETTER

More information

The Economic Club of Florida Tallahassee August 13, 2018 Nancy P Mendenhall, MD. The Promise of Protons

The Economic Club of Florida Tallahassee August 13, 2018 Nancy P Mendenhall, MD. The Promise of Protons The Economic Club of Florida Tallahassee August 13, 2018 Nancy P Mendenhall, MD The Promise of Protons The Promise of Protons Cancer and radiation therapy The promise of protons UFHPTI: missions and operation

More information

The Promise and Pitfalls of Mechanistic Modeling in Radiation Oncology

The Promise and Pitfalls of Mechanistic Modeling in Radiation Oncology The Promise and Pitfalls of Mechanistic Modeling in Radiation Oncology Robert D. Stewart, Ph.D. Associate Professor of Radiation Oncology University of Washington School of Medicine Department of Radiation

More information

COMPARISON OF RADIOBIOLOGICAL EFFECTS OF CARBON IONS TO PROTONS ON A RESISTANT HUMAN MELANOMA CELL LINE

COMPARISON OF RADIOBIOLOGICAL EFFECTS OF CARBON IONS TO PROTONS ON A RESISTANT HUMAN MELANOMA CELL LINE COMPARISON OF RADIOBIOLOGICAL EFFECTS OF CARBON IONS TO PROTONS ON A RESISTANT HUMAN MELANOMA CELL LINE I. Petrovi a, A. Risti -Fira a, L. Kori anac a, J. Požega a, F. Di Rosa b, P. Cirrone b and G. Cuttone

More information

Innovations in Radiation Therapy, including SBRT, IMRT, and Proton Beam Therapy. Sue S. Yom, M.D., Ph.D.

Innovations in Radiation Therapy, including SBRT, IMRT, and Proton Beam Therapy. Sue S. Yom, M.D., Ph.D. Innovations in Radiation Therapy, including SBRT, IMRT, and Proton Beam Therapy Sue S. Yom, M.D., Ph.D. Disclosures Genentech: advisory, research support ImClone: research support Plexxikon: research support

More information

Charged-Particle (Proton or Helium Ion) Radiation Therapy. Original Policy Date

Charged-Particle (Proton or Helium Ion) Radiation Therapy. Original Policy Date MP 8.01.08 Charged-Particle (Proton or Helium Ion) Radiation Therapy Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013

More information

Outline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame

Outline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame Radiation Therapy for Advanced NSC Lung Ca Alexander Gottschalk, M.D., Ph.D. Associate Professor Director of CyberKnife Radiosurgery Department of Radiation Oncology University of California San Francisco

More information

Radiation Treatment Techniques: Where to find rooms for improvement?

Radiation Treatment Techniques: Where to find rooms for improvement? Radiation Treatment Techniques: Where to find rooms for improvement? Cedric Yu, D.Sc. Carl M. Mansfield, M.D. Professor University of Maryland School of Medicine Founder and CEO, Xcision Medical Systems,

More information

Carbon Ion Radiotherapy: Clinical Experiences at National Institute of Radiological Science (NIRS)

Carbon Ion Radiotherapy: Clinical Experiences at National Institute of Radiological Science (NIRS) J. Radiat. Res., 51, 355 364 (2010) Review Carbon Ion Radiotherapy: Clinical Experiences at National Institute of Radiological Science (NIRS) Tohru OKADA*, Tadashi KAMADA, Hiroshi TSUJI, Jun-etsu MIZOE,

More information

The impact of different radiation qualities on cancer cells

The impact of different radiation qualities on cancer cells The impact of different radiation qualities on cancer cells Marjan Moreels, PhD Radiobiology Unit,, Belgium XXth Colloque GANIL Session 10, Amboise, France Oct 19, 2017 1 The Belgian Nuclear Research Center

More information

Radiation qualities in carbon-ion radiotherapy at NIRS/HIMAC

Radiation qualities in carbon-ion radiotherapy at NIRS/HIMAC Radiation qualities in carbon-ion radiotherapy at NIRS/ Shunsuke YONAI Radiological Protection Section Research Center for Charged Particle Therapy National Institute of Radiological Sciences (NIRS) E-mail:

More information

Proton- Radiotherapy: Overview of Clinical Indications

Proton- Radiotherapy: Overview of Clinical Indications Proton- Radiotherapy: Overview of Clinical Indications Eugen B. Hug (with emphasis on indications treated at PSI For comprehensive clinical reviews: ESTRO or PTCOG seminars) HUG 11/07 Complication Free

More information

The Four R s. Repair Reoxygenation Repopulation Redistribution. The Radiobiology of Small Fraction Numbers. The Radiobiology of Small Fraction Numbers

The Four R s. Repair Reoxygenation Repopulation Redistribution. The Radiobiology of Small Fraction Numbers. The Radiobiology of Small Fraction Numbers The Radiobiology of Small Fraction Numbers David J. Brenner, PhD, DSc Center for Radiological Research Columbia University Medical Center djb3@columbia.edu The Radiobiology of Small Fraction Numbers 1.

More information

La ricerca e la terapia in adroterapia-2. R.Orecchia / P. Fossati

La ricerca e la terapia in adroterapia-2. R.Orecchia / P. Fossati La ricerca e la terapia in adroterapia-2 R.Orecchia / P. Fossati Dose (Gy) = energy (joule) / mass (kg) One degree of fever (from 37.5 to 38.5 ) > 4000 Gy RT small dose big damage Photons : Dose Resposne

More information

Stereotactic Ablative Radiotherapy for Prostate Cancer

Stereotactic Ablative Radiotherapy for Prostate Cancer Stereotactic Ablative Radiotherapy for Prostate Cancer Laurie Cuttino, MD Associate Professor of Radiation Oncology VCU Massey Cancer Center Director of Radiation Oncology Sarah Cannon Cancer Center at

More information

The Heidelberg Ion Therapy Center and PARTNER. Thomas Haberer Heidelberg Ion Therapy Center

The Heidelberg Ion Therapy Center and PARTNER. Thomas Haberer Heidelberg Ion Therapy Center The Heidelberg Ion Therapy Center and PARTNER Thomas Haberer Heidelberg Ion Therapy Center Goal The key element to improve the clinical outcome is local control! entrance channel: low physical dose low

More information

Medical Dosimetry Graduate Certificate Program IU Graduate School & The Department of Radiation Oncology IU Simon Cancer Center

Medical Dosimetry Graduate Certificate Program IU Graduate School & The Department of Radiation Oncology IU Simon Cancer Center Medical Dosimetry Graduate Certificate Program IU Graduate School & The Department of Radiation Oncology IU Simon Cancer Center All students accepted into the Medical Dosimetry Graduate Certificate Program

More information

The Rise, Fall, and Rise Again of Proton Therapy or Never count out a well-financed therapy

The Rise, Fall, and Rise Again of Proton Therapy or Never count out a well-financed therapy The Rise, Fall, and Rise Again of Proton Therapy or Never count out a well-financed therapy Anthony Zietman MD Shipley Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School

More information

Dr. Robert R. Wilson, a physicist who had worked on

Dr. Robert R. Wilson, a physicist who had worked on Radiation Therapy With Charged Particles Daniela Schulz-Ertner, MD,* Oliver Jäkel, PhD, and Wolfgang Schlegel, PhD Charged particle beams can offer an improved dose conformation to the target volume as

More information

Innovations in Radiation Therapy, Including SBRT, IMRT and Cancer Proton Bean Therapy

Innovations in Radiation Therapy, Including SBRT, IMRT and Cancer Proton Bean Therapy Innovations in Radiation Therapy, Including SBRT, IMRT and Cancer Proton Bean Therapy Hak Choy, MD Professor and Chairman Department of Radiation Oncology Univ. of Texas Southwestern Dallas Texas Primary

More information

Innovations in Radiation Therapy, Including SBRT, IMRT, and Proton Beam Therapy

Innovations in Radiation Therapy, Including SBRT, IMRT, and Proton Beam Therapy Slide 1 Innovations in Radiation Therapy, Including SBRT, IMRT and Cancer Proton Bean Therapy Hak Choy, MD Professor and Chairman Department of Radiation Oncology Univ. of Texas Southwestern Dallas Texas

More information

Assistant Professor Department of Therapeutic Radiology Yale University School of Medicine

Assistant Professor Department of Therapeutic Radiology Yale University School of Medicine A Mechanism-Based Approach to Predict Relative Biological i Effectiveness and the Effects of Tumor Hypoxia in Charged Particle Radiotherapy David J. Carlson, Ph.D. Assistant Professor Department of Therapeutic

More information

Particle therapy for pancreatic cancer

Particle therapy for pancreatic cancer Review Article Particle therapy for pancreatic cancer R. Charles Nichols Jr The University of Florida Health Proton Therapy Institute, Jacksonville, FL, USA Correspondence to: R. Charles Nichols Jr, MD.

More information

SBRT for lung metastases: Case report

SBRT for lung metastases: Case report SBRT for lung metastases: Case report Guillermo de Velasco MD, PhD University Hospital 12 de Octubre @H12O_GUCancer @g_develasco Case report 71 years old man Smoker DM 2005 Right radical nephrectomy Histology:

More information

Original Date: April 2016 Page 1 of 7 FOR CMS (MEDICARE) MEMBERS ONLY

Original Date: April 2016 Page 1 of 7 FOR CMS (MEDICARE) MEMBERS ONLY National Imaging Associates, Inc. Clinical guidelines STEREOTACTIC RADIATION THERAPY: STEREO RADIOSURGERY (SRS) AND STEREOTACTIC BODY RADIATION THERAPY (SBRT) CPT4 Codes: Please refer to pages 5-6 LCD

More information

The Heidelberg Ion Therapy Center. Thomas Haberer Heidelberg Ion Therapy Center Hadron Therapy Workshop, Erice 2009

The Heidelberg Ion Therapy Center. Thomas Haberer Heidelberg Ion Therapy Center Hadron Therapy Workshop, Erice 2009 The Heidelberg Ion Therapy Center Thomas Haberer Heidelberg Ion Therapy Center Hadron Therapy Workshop, Erice 2009 Goal The key element to improve the clinical outcome is local l control! entrance channel:

More information

Treatment Planning (Protons vs. Photons)

Treatment Planning (Protons vs. Photons) Treatment Planning Treatment Planning (Protons vs. Photons) Acquisition of imaging data Delineation of regions of interest Selection of beam directions Dose calculation Optimization of the plan Hounsfield

More information

4D Radiotherapy in early ca Lung. Prof. Manoj Gupta Dept of Radiotherapy & oncology I.G.Medical College Shimla

4D Radiotherapy in early ca Lung. Prof. Manoj Gupta Dept of Radiotherapy & oncology I.G.Medical College Shimla 4D Radiotherapy in early ca Lung Prof. Manoj Gupta Dept of Radiotherapy & oncology I.G.Medical College Shimla Presentation focus on ---- Limitation of Conventional RT Why Interest in early lung cancer

More information

Chapter 5 Section 3.1

Chapter 5 Section 3.1 Radiology Chapter 5 Section 3.1 Issue Date: March 27, 1991 Authority: 32 CFR 199.4(b)(2), (b)(2)(x), (c)(2)(viii), and (g)(15) 1.0 CPT 1 PROCEDURE CODES 37243, 61793, 61795, 77261-77421, 77427-77799, 0073T

More information

The role of Radiation Oncologist: Hi-tech treatments for liver metastases

The role of Radiation Oncologist: Hi-tech treatments for liver metastases The role of Radiation Oncologist: Hi-tech treatments for liver metastases Icro Meattini, MD Radiotherapy-Oncology Unit AOU Careggi Hospital Florence University, Italy Liver Metastases - Background The

More information

Case Report Carbon Ion Beam Radiotherapy for Sinonasal Malignant Tumors Invading Skull Base

Case Report Carbon Ion Beam Radiotherapy for Sinonasal Malignant Tumors Invading Skull Base Case Reports in Otolaryngology, Article ID 241856, 4 pages http://dx.doi.org/10.1155/2014/241856 Case Report Carbon Ion Beam Radiotherapy for Sinonasal Malignant Tumors Invading Skull Base Nobuo Ohta,

More information

IGRT Protocol Design and Informed Margins. Conflict of Interest. Outline 7/7/2017. DJ Vile, PhD. I have no conflict of interest to disclose

IGRT Protocol Design and Informed Margins. Conflict of Interest. Outline 7/7/2017. DJ Vile, PhD. I have no conflict of interest to disclose IGRT Protocol Design and Informed Margins DJ Vile, PhD Conflict of Interest I have no conflict of interest to disclose Outline Overview and definitions Quantification of motion Influences on margin selection

More information

Proton-Radiotherapy for Tumors of the Skull Base: Indications, Advantages, Limitations

Proton-Radiotherapy for Tumors of the Skull Base: Indications, Advantages, Limitations Proton-Radiotherapy for Tumors of the Skull Base: Indications, Advantages, Limitations Eugen B. Hug, MD Director, Center for Proton-Radiotherapy, Paul Scherrer Institut, Villigen and Chair of Proton-Radiotherapy.

More information

High-precision Radiotherapy

High-precision Radiotherapy High-precision Radiotherapy a report by Professor Cai Grau and Dr Morten Hoyer Department of Oncology, Aarhus University Hospital, Denmark DOI: 10.17925/EOH.2005.0.0.40 Professor Cai Grau Dr Morten Hoyer

More information

Protonterapia e applicazione clinica

Protonterapia e applicazione clinica Protonterapia e applicazione clinica Hadrons since 1993. Hadrontherapy elettrons e Alternatives: hadrons are made by quarks Atom heavy particles radiotherapy particle therapy... Carbon neutrontherapy,

More information

TOPICS. Primary Radiation Therapy. Targeted Therapy in Oncology. Principles of Radiation Therapy. Principles of Radiation Therapy

TOPICS. Primary Radiation Therapy. Targeted Therapy in Oncology. Principles of Radiation Therapy. Principles of Radiation Therapy Peter B. Schiff, M.D., Ph.D. Department of Radiation Oncology Columbia University College of Physicians & Surgeons May 4, 2007 Targeted Therapy in Oncology Surgical Oncology Minimal invasive techniques

More information

New Treatment Research Facility Project at HIMAC

New Treatment Research Facility Project at HIMAC New Treatment Research Facility Project at Koji Noda Research Center for Charged Particle Therapy National Institute of Radiological Sciences IPAC10, Kyoto, JAPAN, 25th May, 2010 Contents 1. Introduction

More information

Proton Radiotherapy for Skull Base and Para-spinal Tumors

Proton Radiotherapy for Skull Base and Para-spinal Tumors Proton Radiotherapy for Skull Base and Para-spinal Tumors Carmen Ares Primary tumors Tumors of the Skull Base - Chordomas, Chondrosarcomas Secondary infiltration or involvement by intracranial tumors -

More information

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017

More information

Neutron Radiotherapy: Past, Present, and Future Directions

Neutron Radiotherapy: Past, Present, and Future Directions Neutron Radiotherapy: Past, Present, and Future Directions Theodore L. Phillips Lecture -- 2014 George E. Laramore Ph.D., M.D. NONE Conflicts of Interest Peter Wootton Professor of Radiation Oncology University

More information

Application of Implanted Markers in Proton Therapy. Course Outline. McLaren Proton Therapy Center Karmanos Cancer Institute McLaren - Flint

Application of Implanted Markers in Proton Therapy. Course Outline. McLaren Proton Therapy Center Karmanos Cancer Institute McLaren - Flint Application of Implanted Markers in Proton Therapy Sung Yong Park, Ph.D. McLaren Proton Therapy Center Karmanos Cancer Institute McLaren - Flint AAPM 2016, SAM Therapy Educational Course, 2016.08.04. Course

More information

Disclosures 5/13/2013. Principles and Practice of Radiation Oncology First Annual Cancer Rehabilitation Symposium May 31, 2013

Disclosures 5/13/2013. Principles and Practice of Radiation Oncology First Annual Cancer Rehabilitation Symposium May 31, 2013 Principles and Practice of Radiation Oncology First Annual Cancer Rehabilitation Symposium May 31, 2013 Josh Yamada MD FRCPC Department of Radiation Oncology Memorial Sloan Kettering Cancer Center Disclosures

More information